




PHARMACEUTICAL 2020

FIVE PRIME THERAPEUTICS INC.
Rank 93 of 358





RealRate

PHARMACEUTICAL 2020

FIVE PRIME THERAPEUTICS INC. Rank 93 of 358

The relative strengths and weaknesses of FIVE PRIME THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIVE PRIME THERAPEUTICS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of FIVE PRIME THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 169%, being 133% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	166,720
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,024
Liabilities, Non-Current	0
Other Assets	34,888
Other Compr. Net Income	184
Other Expenses	0
Other Liabilities	0
Other Net Income	4,736
Other Revenues	14,874
Property and Equipment	22,534
Research and Development	114,063
Selling, General and Administrative Expense	42,749

Output Variable	Value in 1000 USD
Assets	224,142
Liabilities	23,024
Expenses	156,812
Revenues	14,874
Stockholders Equity	201,118
Net Income	-137,202
Comprehensive Net Income	-137,110
Economic Capital Ratio	169%